were present in the HVC of adult male canaries, almost no BDNF immunostaining was observed in the HVC of adult females.
Results
Given the abundance of the BDNF receptor, TrkB, and the fact that immunolabeling was carried out with a The Occurrence of TrkB and BDNF in the HVC of Adult Canaries neutralizing antibody to BDNF (which competes with TrkB for BDNF), one potential reason for the low levels We carried out immunohistochemistry for BDNF and TrkB on parasagittal sections of the brains of adult male of immunostaining seen in the HVC could have been the masking of BDNF due to receptor binding. We therefore and female canaries killed in the spring and perfused with saline and paraformaldehyde (Figure 1 ). All animals repeated the immunohistochemical protocol using sections from canary brains perfused with acetate-buffered were carefully monitored and prevented from singing for a period of 2 hr before perfusion, in order to minimize saline (ABS) and paraformaldehyde. ABS has previously been shown to improve neurotrophin immunolabeling any effect that singing might have on BDNF protein levels, a precaution dictated by the observation that by dissociating the receptor from the neurotrophin (Zhou et al., 1994) . BDNF immunostaining in the HVC of adult BDNF mRNA levels in the HVC are upregulated by singing and return to basal levels about 2 hr after the animals male canaries was found to be greatly enhanced by ABS treatment, suggesting that much of the BDNF in the stop singing (Li et al., 1997).
Several regions were positive to BDNF and TrkB, and a HVC is normally bound to its receptor. However, ABS treatment destroyed cellular morphology in the HVC, complete inventory of these regions is shown elsewhere (Rasika, 1998). In the present report, we focus only on and it was therefore not possible to determine if the H-thymidine twice daily for 5 days to label a large contingent of new neurons, then waited 25 days from the first injection to allow the cells to migrate (Figure 2A) . On day 25, we started infusion of either BDNF or saline immediately lateral to the HVC using an osmotic pump ( Figure 2C ). Birds were killed after 10 days of infusion. Cannulas did not result in lesioning of the HVC. The extent of the infusion could not be determined by immunohistochemistry for BDNF, possibly due to degradation or antigen masking in PEG embedded tissue. However, BDNF diffuses only a few millimeters in the mammalian brain parenchyma (Mufson et al., 1994; Sobreviela et al., 1996) , which would have been enough in this case to cover the HVC and some neighboring areas, such as the shelf and cHV, but not to affect more distant regions. Neuronal identity was based on morphology in cresyl violet-stained sections. Cells containing large, regular, clear nuclei with one or two darkly staining nucleoli were considered to be neurons (Goldman and Nottebohm, 1983), and neurons with more than 20ϫ background levels of silver grains were counted as 3 H-thymidine labeled (Figure 3) . BDNF infusion had several significant effects on the HVC (Figure 4) . The HVC volume of the BDNF-treated females was larger than that of controls, by 58% in the spring and 68% in the fall (P-value for infusate ϭ 0.0003; ANOVA); there were no significant volume differences with season (P-value for season ϭ 0.5649; ANOVA). BDNF infusion increased the nuclear diameters of all HVC neurons from 6.77 to 7.41 m in the spring and from 6.57 to 7.30 m in the fall (P-value for infusate Ͻ suggests that BDNF levels may be affected by maleThere was no obvious gradient of 3 H-thymidine-labeled specific factors such as testosterone. This possibility, neurons in the HVC with respect to the infusion site, plus the observation that both testosterone (Rasika et suggesting that the infused BDNF reached all parts of al., 1994) and BDNF increase neuronal recruitment in the HVC. Even though the absolute number of new HVC the female HVC, led us to test whether testosterone neurons was higher in the spring than in the fall, the might increase BDNF levels in the HVC. To this end, we percentage of new neurons in each of the two treatment treated adult female canaries with empty or testostergroups (control and BDNF-treated) was similar in both one-filled implants for 3 weeks in the fall (October), perseasons, respectively: 1.59% and 1.48% in the control fused these animals with ABS and saline 2 hr after they group and 4.16% and 3.55% in the BDNF-treated group.
were prevented from singing, and carried out immunoThus, the effect of BDNF was not season dependent, staining for BDNF. As in the spring, the control females even though the physiological condition of the spring had a small, relatively flat HVC with little or no BDNF. In and fall females (onset of breeding season and end of contrast, the testosterone-treated females had a larger molt, respectively) differed markedly.
HVC ( Figure 2C . Birds in the second group also received infusion of carrier solution but were given testosteronefilled implants. Birds in the third group were given testosterone-filled implants but received an infusion of a neutralizing antibody to BDNF (␣-BDNF). Hormonal treatments and infusion were carried out for 10 days, at which point the animals were sacrificed.
HVC volume was increased to a small but significant extent (18%) by testosterone treatment but was retained at its original level by ␣-BDNF infusion (P-value ϭ 0.0155; Kruskal-Wallis test) (Figure 7) . The HVC volume of the birds in this experiment that received only saline was larger than that of the controls shown in Figure 4 . The two experiments were done on different years. We do not know what accounted for the differences in control HVC volume, but this measure is sensitive to histological processing, to time of year (in males), and possibly also to housing conditions. Importantly, each group of birds that underwent an experimental procedure had its own controls, kept under similar conditions and processed at the same time. The effects of testosterone that we report here are in the same direction as those reported in an earlier publication (Rasika et al., 1994) .
The nuclear diameters of all HVC neurons were also 
1988). occurrence of labeled neurons with respect to distance
There was an 8% and 33% increase in the total numfrom the infusion site. From the changes in volume and ber of HVC neurons of birds treated with BDNF in the packing density, we infer that the total number of these spring and fall, respectively. These increases are connew neurons in the HVC doubled after the 10 days of gruent with our observation that BDNF treatment restestosterone treatment. This testosterone-induced incued cells that otherwise would have died. However, crease was prevented in the ␣-BDNF-infused females the observed increases were not significant, and larger (P-value ϭ 0.0087; Kruskal-Wallis test) (Figure 7) . sample sizes may be needed to determine whether or not BDNF leads to a net increase in HVC neuron number. Discussion
Our infusion experiment showed that the greater part
The This similarity is surprising given that, due to methodTestosterone and BDNF given over a comparable peological constraints, the protocols used in the two studriod of time affect neuronal survival to different extents. ies differed. Two plausible interpretations come to mind:
Adult female canaries treated systemically with testoseither the two molecules act through similar mechaterone for 10 days achieve a mere 18% increase in HVC nisms, or BDNF mediates the effects of testosterone.
volume and a 2-fold increase in neuronal recruitment; The latter interpretation is supported by the fact that BDNF infused next to HVC also for 10 days induces a testosterone treatment increases BDNF immunopositiv-60% increase in HVC volume and a 3-fold increase in ity in the HVC of females. If BDNF levels are secondary the number of labeled neurons. These two experiments to those of testosterone, this would explain the sexual cannot be readily compared because of the two different dimorphism in HVC's BDNF protein levels. Support for manners of drug administration. However, a possible this view also comes from the observation that BDNF inference is that systemic testosterone induces lower mRNA levels in the HVC of male canaries are higher in levels of BDNF in the HVC than direct infusion or that the spring than in the fall and apparently under the conthere is a delay between the rise in testosterone and trol of testosterone (S. R., F. N., and A. A.-B., unpub- the subsequent rise in BDNF levels. A separate study lished data).
has shown that singing also upregulates BDNF in the The effect of testosterone on BDNF expression could HVC ( were anesthetized deeply as described and perfused with ABS and 3% paraformaldehyde. Immunohistochemistry for BDNF was carried out as described above. Infusion of BDNF into the HVC Four groups of three 1-year-old female canaries (two groups each for March and October) were injected intramuscularly with 50 l of Infusion of ␣-BDNF into the HVC 3 H-thymidine (1 mCi/ml; New England Nuclear) twice daily for 5 days. Three groups each of five 1-year-old female canaries were injected 25 days after the first injection, osmotic pumps and cannulas were twice daily for 5 days with 3 H-thymidine as described before. 25 implanted into animals anesthetized by intramuscular injection of days after the first injection, in October, osmotic pumps and cannuNembutal (pentobarbital, 25 mg/kg body weight; Abbot Laboralas were implanted into anesthetized animals; testosterone-filled or tories), followed by inhalation of Metofane (methoxyflurane; Malempty Silastic implants made as described above were subcutanelinckrodt Veterinary). The flowrate of Alzet 1007D osmotic miniously implanted at the same time. The first group received osmotic pumps (Alza Corporation) was reduced to 0.4 l/hr by immersing pumps containing carrier (0.9% saline with 20 g/ml BSA) and empty them in molten paraffin (Sigma) at 60ЊC to a depth of 7 mm (Vahlsing Silastic implants, the second group received osmotic pumps conet al., 1989), and pumps were filled with 100 l of 3 mg/ml human taining carrier, but testosterone-filled Silastic implants, while the recombinant BDNF (Amgen) in a carrier of 0.9% saline with 20 g/ third group received testosterone-filled Silastic implants and osml BSA (Sigma), or carrier alone. Such a setup delivers about 28.8 motic pumps containing 10 g/ml of the BDNF antibody (AB1513P, g/day of BDNF, which is well within the range used by infusion Chemicon) in carrier. Animals were sacrificed 10 days after infusion studies in mammals (Mufson et 
